RecruitingPhase 4NCT06128915

The Role of Neutrophils in the Age-driven Decline in Anti-pneumococcal Vaccine Responses

Sponsor

State University of New York at Buffalo

Enrollment

60 participants

Start Date

Jan 8, 2024

Study Type

INTERVENTIONAL

Conditions

Aging

Summary

This study focuses on the role of neutrophils in shaping the adaptive immune response to the anti-pneumococcal vaccine Prevnar-13 in young and elderly adults.

Eligibility

Min Age: 21 Years

Inclusion Criteria7

Both sexes
Have not been vaccinated with any licensed or experimental pneumococcal vaccine
Ages 21-40; and ≥65. Individuals \>60 years old will also be recruited in case we find no unvaccinated people ≥65 years old
Free of acute infections within the last 2 weeks
Did not take any anti-inflammatory medicine in the last week
Did not ingest alcohol in the last 24 hours
Ability and willingness to provide consent

Exclusion Criteria10

Previous vaccination with any licensed or experimental pneumococcal vaccine
Known hypersensitivity to vaccination and vaccine components
Immune deficiency
Use of immune-modulating or suppressive drugs
Malignancies within the last 2 years
Known hematological, rheumatic and inflammatory diseases
Known chronic infections
Poorly controlled chronic cardiovascular and metabolic conditions
Pregnancy
Dementia

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERvaccine

Vaccination against 20 serotypes of S. pneumoniae

Locations(1)

University at Buffalo

Buffalo, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06128915

Related Trials

Effects of Physical Exercise and a Nutritional Supplement on Body Composition, Metabolic Function, and Overall Health in Adults With a Metabolically Challenging Profile

NCT075040681 location

Baltimore Longitudinal Study of Aging

NCT002332721 location